PSA Levels by Age Chart: Normal Range for Men 40–79

If a PSA result has just arrived, the first question is usually whether the number is normal for your age. The chart below gives the age-based reference ranges most often quoted, where they come from and, just as important, what they cannot tell you. For the wider picture, see our prostate health hub.

This guide covers the age chart and its source, why a result under the range is not a guarantee, what raises PSA without cancer, how finasteride and dutasteride change the number, what the evidence says about tracking PSA over time, and what the main guidelines say about who should be tested. It is general information, not a diagnosis. Your own doctor can see the full picture.

PSA Levels by Age Chart

The most widely quoted age-specific reference ranges come from a community study in Olmsted County, Minnesota. Researchers measured PSA in 471 men aged 40 to 79 who showed no evidence of prostate cancer on a PSA test, a digital rectal exam or transrectal ultrasound, and reported the 95th percentile for each decade of age [1].

In other words, about 95 in 100 of the healthy men in that study had a PSA at or below the limit for their age, and about 5 in 100 sat above it. The authors' reasoning was that PSA rises with both age and prostate volume (the correlations were r = 0.43 and r = 0.55), so a single cut-off for every man is a blunter tool than ranges that account for age. For a healthy 60-year-old man with no evidence of prostate cancer, PSA rose by about 3.2% per year (roughly 0.04 ng/mL per year) in that study [1].

Three limits matter when you apply this chart. First, it describes one group of men in one community, measured with one specific assay [1], so treat the limits as a reference point and ask your doctor how your own lab's result is read. Second, the study did not include men over 79. Third, a reference range describes healthy men. It does not mark the point where cancer starts.

A Result Under the Range Is Not a Guarantee

The Prostate Cancer Prevention Trial produced an unusual dataset. Among 2,950 men aged 62 to 91 in the placebo group who never had a PSA above 4.0 ng/mL or an abnormal rectal exam, and who had a biopsy after seven years in the study, prostate cancer was found in 449 (15.2%). Of those cancers, 67 (14.9%) had a Gleason score of 7 or higher [2]. The chance of finding cancer rose steadily with PSA, even inside the range most people call normal:

Read this table carefully. These men were trial participants who had a biopsy whether or not anyone suspected cancer, and most of the cancers found were lower grade. It does not mean a PSA of 3.5 carries a 27% chance of dangerous cancer. It does mean there is no PSA value below which cancer is ruled out, so a result inside the chart is reassuring but not conclusive [2]. The same ability that lets PSA find small, low-grade, localised tumours has also fuelled debate over whether insignificant cancers are being diagnosed and treated [3].

What Raises PSA Without Cancer

PSA is made by prostate tissue, healthy or not, so anything that affects the prostate can move the number. A review of PSA's limitations lists enlarged prostate volume with ageing (BPH), urinary retention, acute and chronic prostate inflammation, sexual activity and digital rectal examination as all able to raise it [4].

• •Prostate size: in the Minnesota data, PSA correlated with prostate volume (r = 0.55) as well as with age [1]. A large benign prostate can produce a higher PSA with no cancer present [4].
• •Ejaculation: in a study of 98 men with urinary symptoms, total PSA differed from baseline at 1 and 5 hours after ejaculation, while the number of men crossing the cut-off did not change significantly. The authors noted it could still matter for results sitting close to a cut-off [5].
• •Inflammation and examination: prostate inflammation and a recent digital rectal exam can both raise PSA [4]. Tell whoever orders the test about any urinary infection, symptoms or recent examination.

Ask your doctor whether you should avoid ejaculation or other pressure on the prostate before the blood draw, and whether a repeat test makes sense if a result is unexpectedly high before any bigger step is taken.

Finasteride and dutasteride

The 5-alpha reductase inhibitors finasteride and dutasteride, used to treat BPH, lower serum PSA by close to 50% [4]. Studies show finasteride cuts PSA by about 50% during the first 12 months, and in the Prostate Cancer Prevention Trial the adjustment factor needed to restore the median PSA rose from 2 at 24 months to 2.5 at seven years [6]. A review of trial data concluded that the accuracy of PSA testing is maintained, and if anything increased, during treatment with these drugs [4]. Tell whoever reads your result which one you take so they can interpret it correctly.

PSA Velocity: What the Evidence Actually Shows

You will often see a rise of more than 0.75 ng/mL per year quoted as a warning sign for cancer. That figure traces to a 1992 study of 54 men (16 with no prostate disease, 20 with BPH and 18 with prostate cancer) whose stored blood samples were measured 7 to 25 years before diagnosis. The authors reported that a rate of change of 0.75 µg/L per year (the same unit as ng/mL) was significantly greater in men who later had cancer than in men with BPH or controls, and that rate of change distinguished the groups with a specificity of 90% and 100% [7].

It was a small study, and later work has been less encouraging. A 2012 review by Vickers and Brewster found that calculating PSA velocity and doubling time is 'far from straightforward': more than 20 methods have been proposed and many give divergent results. It concluded that PSA kinetics have no role in diagnosing prostate cancer, or judging prognosis, in men who have not yet been treated. They are, the review said, critical for understanding prognosis after treatment or in advanced or relapsed disease [8].

So a rising PSA is a reason to talk to your doctor, not a diagnosis, and a flat one is not a guarantee. Keeping your results together (date, value, laboratory and any relevant medicines) still helps that conversation.

Free PSA When the Total Is 4 to 10 ng/mL

When total PSA falls between 4 and 10 ng/mL, doctors sometimes also measure the percentage of PSA that circulates unattached to proteins (free PSA). In a multicentre study of 773 men aged 50 to 75 with a benign-feeling prostate and a PSA of 4.0 to 10.0 ng/mL, a cut-off of 25% free PSA detected 95% of cancers while avoiding 20% of unnecessary biopsies. The cancers found above 25% were more common in older men and generally less threatening in grade and volume [9]. Our free PSA ratio guide goes into more detail.

If Your PSA Is Above the Range

A number above the reference limit for your age is a reason for a conversation, not a diagnosis. The chart marks where 95% of healthy men in one study fell, and benign conditions can push PSA over it [1][4]. Questions worth bringing to your doctor:

• •Could a medicine (especially finasteride or dutasteride), recent ejaculation, an infection or a recent rectal exam explain the result?
• •Does a repeat test make sense before anything else is done?
• •Would free PSA or an MRI scan help decide whether a biopsy is needed?
• •Should I see a urologist, and how soon?

One trial worth knowing about is PRECISION. It randomised 500 men with a clinical suspicion of prostate cancer who had not had a biopsy to either MRI (with a targeted biopsy if the scan was suspicious) or standard ultrasound-guided biopsy. Clinically significant cancer was found in 38% of the MRI-targeted group versus 26% of the standard-biopsy group, and 28% of the MRI group had a scan that was not suggestive of cancer and avoided biopsy altogether [10]. Whether MRI is the right route for you is a decision for you and your urologist.

What to Expect at a Urology Appointment

If your doctor refers you to a urologist, the visit usually covers the following:

• •A review of your history: urinary symptoms, family history, and every medicine and supplement you take, especially finasteride or dutasteride, which lower PSA [4].
• •A digital rectal exam, in which the doctor feels the prostate through the rectum.
• •Possibly a repeat PSA, and a discussion of whether further testing such as free PSA or an MRI would help [9][10].
• •A conversation about whether a biopsy is needed and which kind, including the benefits and risks of each option.

PSA After Prostate Cancer Treatment

PSA testing has also changed how doctors monitor the response to treatment and detect recurrence [3]. After a radical prostatectomy, doctors watch for a detectable and rising PSA: in a retrospective review of 1,997 men, a PSA of at least 0.2 ng/mL was taken as evidence of biochemical recurrence [13]. After radiotherapy, PSA falls slowly to a lowest point called the nadir, and a rise of 2 ng/mL or more above the nadir is the consensus definition of biochemical failure [14]. Our guide to PSA velocity and doubling time explains what the research says about PSA trends after diagnosis and treatment.

Keep Your Own PSA Record

• •Write down the date, the exact value and the laboratory for every result.
• •Note medicines, especially finasteride or dutasteride, and anything that might have affected a particular result, such as an infection, a recent rectal exam or recent ejaculation [4][5].
• •Ask your doctor for the actual number, not just 'normal' or 'abnormal'.
• •Bring the whole list to appointments. It gives your doctor context for each new result.

Who Should Be Tested? What the Guidelines Say

Guidelines do not give one starting age for every man, and they stress that PSA screening is a personal decision. The US Preventive Services Task Force (2018) concluded that for men aged 55 to 69 the decision should be an individual one made with a clinician. Its review found that screening may prevent about 1.3 deaths from prostate cancer per 1,000 men screened over roughly 13 years, weighed against false-positive results, overdiagnosis and treatment effects such as incontinence and erectile dysfunction. For men 70 and older it concluded that the potential benefits do not outweigh the expected harms. It also notes that African American men and men with a family history of prostate cancer have an increased risk [11].

The 2023 AUA/SUO guideline recommends PSA-based screening combined with shared decision-making [12]. Those statements date from 2018 and 2023, so ask your doctor which guidance applies to you now. Your risk, family history and preferences matter more than any chart.

Supplements do not change what a PSA number means, and none of the products below is a PSA treatment or a substitute for testing. If you take any supplement, tell your doctor.